Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies

• Main Authors: Lourdes Farre (Author), Gabriela Sanz (Author), Neus Ruiz-Xivillé (Author), Manuel Castro de Moura (Author), Juan Francisco Martin-Tejera (Author), Samuel Gonçalves-Ribeiro (Author), Maria Martinez-Iniesta (Author), Monica Calaf (Author), Jose Luis Mosquera (Author), José Ignacio Martín-Subero (Author), Isabel Granada (Author), Manel Esteller (Author), Eva Domingo-Domenech (Author), Fina Climent (Author), Alberto Villanueva (Author), Anna Sureda (Author)
• Formato: Libro
• Publicado: The Company of Biologists, 2021-07-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well-characterized preclinical models for...